Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peroxiredoxin 2
- Development stage
- Preclinical
- Lead developer
- University of California, Los Angeles
- Modality
- Gene Therapies
- Administration
- Parenteral
01
Overview
Peroxiredoxin 2 (PRDX2) is a thiol-specific antioxidant enzyme that reduces peroxides to alcohols, playing a key role in cellular redox homeostasis and antioxidant defense. In the context of Crohn's disease (CD), PRDX2 has been identified as an anti-fibrogenic factor that is downregulated in patients with intestinal strictures. Research indicates that PRDX2 expression can be induced by the metabolite inosine via the adenosine 2A receptor (A2AR). PRDX2 acts by reducing cellular stress and inducing cyclooxygenase-2 (COX-2), which subsequently inhibits collagen expression in human ileal fibroblasts. Therapeutic approaches under investigation include lentiviral-mediated gene overexpression of PRDX2 to ameliorate intestinal fibrosis, as demonstrated in preclinical SAMP1/YitFc mouse models.
- Other names
- peroxiredoxin-2peroxiredoxin2peroxiredoxin 2thiol-specific antioxidant protein 1TSAPRPNKEFB
02
Targets
TXN (Thioredoxin-1)STAT3 (Signal Transducer and Activator of Transcription 3)
Beyond the preview
Go deeper on peroxiredoxin 2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peroxiredoxin 2.